Aurobindo Pharma’s $900 Million Acquisition of Novartis’ Sandoz Generic Assets

Ambrogio Visconti

Baker Botts advised Novartis on the sale Novartis today has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here